Daratumumab binding to CD38 on tumor cells induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, tumor cell apoptosis, and CD38 enzymatic activity regulation [4]. The gene discussed is CD38; the disease is neoplasm.